Bru-nO / Pixabay

Synlogic Halts Development of Investigational Hyperammonemia Treatment SYNB1020

Post author:Scott Carlson
Post published:August 26, 2019
Post category:Hepatic encephalopathy Hyperammonemia due to NAGS deficiency Rare Disease

According to a press release from Synlogic Therapeutics, the Company recently halted development of its investigational hyperammonemia treatment SYNB1020 after an unsuccessful phase 1/2 clinical study. About Hyperammonemia Hyperammonemia is…

Get Involved

Ready to get involved with Patient Worthy? Share your authentic story with others. Raise awareness and inspire change!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Get Involved

Synlogic Halts Development of Investigational Hyperammonemia Treatment SYNB1020

Metastatic Breast Cancer: Navigating Grief

Rethinking What It Means to Live With Acromegaly

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

Get Involved

Let’s Work Together!

Keep Up to Date

Learn More